A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Benefits of ensitrelvir in Covid-19 and long Covid highlighted in two studies
The benefits of ensitrelvir use in patients with symptoms of long Covid and as a second-line treatment option for those hospitalised with Covid-19.
Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
|
9th Influenza Conference 2023
The Influenza B/Yamagata lineage appears to become extinct: implications for quadrivalent influenza vaccines?
SPI08 session from #ESWI2023
|
9th Influenza Conference 2023
Meet the first winners of ESWIs Diversity Equity and Inclusion Award
ESWI is pleased to announce the five winners of the Award in Recognition of Diversity Equity and Inclusion.
|
9th Influenza Conference 2023
Meet the winner of the Young Scientist Vaccine Innovation Award: Jenna Guthmiller
Jenna Guthmiller, Assistant Professor at the University of Colorado Anschutz, has been selected as the third recipient of the Early Career Scientist Vaccine Innovation Award, for her innovative work around vaccination and immunity.
|
9th Influenza Conference 2023
Meet the winner of the Claude Hannoun prize for Best Body of Work: Carolien van de Sandt
The seventh edition of Claude Hannoun Prize for Best Body of Work goes to Carolien van de Sandt, Peter Doherty Institute, University of Melbourne (Australia)...
|
9th Influenza Conference 2023
Communication: Raising awareness on the burden of disease
Scientific communication is critical for promoting scientific literacy and facilitating informed decision-making among the public.
|
9th Influenza Conference 2023
Next on the Influenza Virus Vaccine Horizon: A Slow Releasing Antigen Concept
Mimicking vaccine delivery kinetics of natural infection: extending the delivery of influenza virus antigens
